NDLI: Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.

Please wait, while we are loading the content...

Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.

Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer.

Clinical characteristics of pleomorphic carcinoma of the lung.

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.

Relationships between lung adenocarcinoma and gender, age, smoking and occupational risk factors: A case-case study.

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?

Combining transbronchial biopsy using endobronchial ultrasonography with a guide sheath and positron emission tomography for the diagnosis of small peripheral pulmonary lesions.

Restoration of leukotriene B(4)-12-hydroxydehydrogenase/15- oxo-prostaglandin 13-reductase (LTBDH/PGR) expression inhibits lung cancer growth in vitro and in vivo.

Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer.

Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens.

Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.

Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.

Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.

Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience.

Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.

Every-day clinical practice in patients with advanced non-small-cell lung cancer.

Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.

Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis.

Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea.

A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.

Angiogenic markers in breath condensate identify non-small cell lung cancer.

Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy.

Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).

An investigation on electronic nose diagnosis of lung cancer.

Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review.

Radiotherapy for lung cancer in the elderly.

Exhaled ERCC-1 and ERCC-2 microsatellite alterations in NSCLC patients.

Smells like cancer.

Year: 2010 Volume: 68 Issue: 1

Year: 2010 Volume: 67

Year: 2009 Volume: 66

Year: 2009 Volume: 65

Year: 2009 Volume: 64

Year: 2009 Volume: 63

Year: 2008 Volume: 62

Year: 2008 Volume: 61

Year: 2008 Volume: 60

Year: 2008 Volume: 59

Year: 2007 Volume: 58

Year: 2007 Volume: 57

Year: 2007 Volume: 56

Year: 2007 Volume: 55

Year: 2006 Volume: 54

Year: 2005 Volume: 49

Year: 2005 Volume: 48

Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Kappers, Ingrid Van Sandick, Johanna W. Burgers, Sjaak A. Belderbos, José S. A. Van Zandwijk, Nico Klomp, Houke M.
Description	Country affiliation: Netherlands Author Affiliation: Kappers I ( Department of Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. i.kappers@nki.nl)
Abstract	BACKGROUND: The role of surgery in the treatment of patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) is a hot topic. Since variable results of surgery versus radiotherapy after induction chemotherapy are being reported, this study aimed to analyze results of surgery after induction chemotherapy and to identify relevant factors influencing outcome in patients with stage IIIA NSCLC. METHODS: Patients with stage IIIA (N2) NSCLC, treated with platinum-based induction chemotherapy between 1994 and 2006, were identified. By a retrospective review of hospital records, response to induction treatment, short-term outcome, recurrence of disease and survival were evaluated. RESULTS: Ninety-nine patients, 66 men and 33 women, were identified. Median follow-up was 54 months (range 13-129). Median age at treatment was 62 (range 36-77). Mediastinal downstaging was seen in 32 patients. Forty-three patients received radical radiotherapy and 39 patients underwent surgery: 19 pneumonectomies, 19 lobectomies and one exploratory thoracotomy. Microscopic complete resection (R0) was reached in 30 patients. Pathological response to induction therapy was CR in 5%, PR in 59% and SD in 36%. Postoperative mortality was 3%. The 1-year mortality was 26% after pneumonectomy and 11% after lobectomy. Five-year survival after surgery was 28%, and was better after lobectomy than after pneumonectomy (43% versus 16%; p=0.03). Other factors as age, weight loss, clinical mediastinal downstaging, radicality, and histology did not substantially contribute to this difference. CONCLUSION: Type of surgical resection was the major factor influencing outcome in patients with stage IIIA (N2) NSCLC after induction chemotherapy. These results suggest that patients with stage IIIA (N2) NSCLC may benefit from surgical resection, as long as a lobectomy can be performed.
File Format	HTM / HTML
ISSN	01695002
Issue Number	2
Volume Number	68
e-ISSN	18728332
Journal	Lung Cancer
Language	English
Publisher	Elsevier
Publisher Date	2010-05-01
Publisher Place	Ireland
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Oncology Carcinoma, Non-small-cell Lung Surgery Chemotherapy, Adjuvant Lung Neoplasms Pneumonectomy Contraindications Adult Aged Drug Therapy Mortality Pathology Physiopathology Cisplatin Therapeutic Use Deoxycytidine Analogs & Derivatives Female Follow-up Studies Humans Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Retrospective Studies Survival Analysis Journal Article
Content Type	Text
Resource Type	Article
Subject	Pulmonary and Respiratory Medicine Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt

Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.

Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?

Pneumonectomy for node-positive non-small cell lung cancer: can it be a treatment option for N2 disease?

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.

What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).

Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.

Similar Documents

Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt

Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.

Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?

Pneumonectomy for node-positive non-small cell lung cancer: can it be a treatment option for N2 disease?

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.

What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).

Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.